SOURCES SOUGHT
65 -- Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration
- Notice Date
- 3/22/2018
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical - BSM, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- SPE2DP-18-R-0150
- Archive Date
- 5/10/2018
- Point of Contact
- Matheu C. Wilson, Phone: (215) 737-5654, Amanda Doherty, Phone: (215) 737-9508
- E-Mail Address
-
matheu.wilson@dla.mil, amanda.doherty@dla.mil
(matheu.wilson@dla.mil, amanda.doherty@dla.mil)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Notice for the Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration The Defense Logistics Agency - Troop Support (DLA-TS) is seeking sources capable of providing the Adenovirus Vaccine, NSN 6505-01-642-0106. Accordingly, DLA-TS is contemplating awarding an Indefinite Delivery-Indefinite Quantity (IDIQ) contract for the Adenovirus Vaccine with a one-year base period and four (4) one-year option periods. The vaccine shall be live, bivalent, enteric-coated tablets, intended for active immunization for the prevention of respiratory infections caused by the Adenovirus types 4 and 7, suitable for oral administration only. The estimated annual quantity to be ordered is 2,223 Packages (222,300 doses/ 444,600 tablets); however, the quantity may increase or decrease considerably as the requirements are subject to change. A package (PG) consists of two (2) bottles - one (1) bottle of 100 tablets each of Adenovirus Type 4 and one (1) bottle of 100 tablets each of Adenovirus Type 7. Additionally, one (1) dose shall constitute two (2) tablets - one (1) tablet each of Adenovirus Type 4 and Adenovirus Type 7, or 100 doses per PG. The anticipated annual guaranteed minimum purchase quantity is estimated to be 2,178 PG (217,800 doses), and the anticipated annual guaranteed maximum is estimated to be 2,268 PG (226,800 doses). The quantities indicated above are annual estimates only. Additional specification data will be included in any resultant solicitation, once issued. The successful offeror shall have Federal Drug Administration (FDA) approval to supply the requisite Adenovirus vaccine prior to contract award. Ordered quantities shall be delivered to various military activities throughout the United States. Delivery is scheduled on a monthly basis to these activities. First deliveries shall begin 3-6 months after contract award, or best available delivery negotiated between the contractor and the government. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by DLA-TS. If your firm currently manufactures or distributes the Adenovirus vaccine, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the Adenovirus vaccine or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA-TS. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the Adenovirus. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in PDF format and emailed to both Amanda Doherty (Amanda.doherty@dla.mil), and Mat Wilson (matheu.wilson@dla.mil).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M-BSM/SPE2DP-18-R-0150/listing.html)
- Record
- SN04863965-W 20180324/180322231531-be8f766902ce03614c59a36c63e3a006 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |